A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin R U-500 and Humalog Mix 75/25 in Subjects With Type 2 Diabetes Mellitus Who Are Treated With 50-200 Units of Insulin Per Day

Trial Profile

A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin R U-500 and Humalog Mix 75/25 in Subjects With Type 2 Diabetes Mellitus Who Are Treated With 50-200 Units of Insulin Per Day

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2016

At a glance

  • Drugs Insulin (Primary) ; Insulin neutral protamine lispro/insulin lispro
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Biodel
  • Most Recent Events

    • 08 Oct 2014 New trial record
    • 11 Aug 2014 Positive preliminary results published in Biodel media release.
    • 11 Aug 2014 Status changed from active, no longer recruiting to completed, according to a Biodel media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top